CGM – Medxy AI

Cost-Effectiveness of Continuous Glucose Monitoring Combined with Remote Patient Monitoring in Pediatric Type 1 Diabetes

By MedXY 05/03/2026

A landmark simulation study demonstrates that adding remote patient monitoring to continuous glucose monitoring in pediatric T1D patients significantly improves QALYs and is highly cost-effective compared to standard care.

Diabetes & Endocrinology news

Why Time Below Range Is a Poor Standalone Predictor of Severe Hypoglycemia: Evidence from Six Clinical Trials

By MedXY 03/17/2026

A multi-trial analysis reveals that CGM-derived Time Below Range (TBR) lacks the predictive power to serve as a standalone biomarker for severe hypoglycemia, highlighting the need for multi-factorial risk assessment in Type 1 Diabetes.

Diabetes & Endocrinology Specialties

What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care

By MedXY 08/22/2025

A practical, clinician-friendly summary of the American Diabetes Association’s 2024 Standards of Care, highlighting new recommendations on GLP-1/GIP therapy, SGLT2 inhibitors, continuous glucose monitoring, and individualized care.